convulex 150 mg kapsuly
g.l. pharma gmbh, rakúsko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
convulex 300 mg kapsuly
g.l. pharma gmbh, rakúsko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
convulex 500 mg kapsuly
g.l. pharma gmbh, rakúsko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
convulex 300 mg/ml kvapky
g.l. pharma gmbh, rakúsko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
orfiril long 150 mg
desitin arzneimitttel gmbh, nemecko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
orfiril long 300 mg
desitin arzneimitttel gmbh, nemecko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
orfiril long 500 mg
desitin arzneimitttel gmbh, nemecko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
orfiril long 1000 mg
desitin arzneimitttel gmbh, nemecko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
valpro-ratiopharm chrono 500 mg
ratiopharm gmbh, nemecko - kyselina valproová - 21 - antiepileptica, anticonvulsiva
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).